Drug Approval | June 22, 2024
Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
EDQM has also issued a Certificate of Suitability for Allopurino
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Prior to taking charge at the Union Health Ministry, Jadhav planted a sapling at his residence
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Greg was also central to the planning, design, and construction of this facility
Subscribe To Our Newsletter & Stay Updated
